6 employees
ValenzaBio is developing safe and effective treatment options for patients with autoimmune and inflammatory diseases.
2019
$79M
from 3 investors over 3 rounds
ValenzaBio raised $79M on April 8, 2021
Investors: Ikarian Capital LLC, Pierre Fabre and Surveyor Capital